Is there a large number of people taking Erdafitinib/Bocco?

Erdafitinib is mainly targeted at patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) carrying FGFR3 gene alterations. Patients with this type of genotype account for a relatively limited proportion of the overall population of advanced urothelial cancer. However, due to the high recurrence and advanced course of urothelial cancer, these patients still have a significant clinical need for targeted therapy. Globally, the number of users of erdafitinib is gradually increasing, especially in European and American countries and parts of Asia. After suitable patients are identified through genetic screening, its accurate application rate continues to increase.

In China, due to the large base of patients with advanced urothelial cancer and the gradual popularization of FGFR3 gene mutation testing, the potential applicable population of erdafitinib has gradually become clear. However, because the drug has just been launched and has not yet been included in medical insurance, and companion diagnostics are required to determine suitability, the number of people actually using it is relatively limited. Most patients receive treatment through large hospitals or specific imported drug channels, and doctors often strictly screen in clinical practice to ensure that patients can get the maximum benefit from the drugs.

In addition, with the popularization of genetic testing technology and the promotion of precision medicine concepts, the base of applicable patients for erdafitinib is expected to gradually expand. Clinical studies and real-world data also show that the drug can delay disease progression and improve quality of life when used by suitable patients, thus stimulating the attention of more advanced patients and clinicians. In the future, if medical insurance coverage or generic drugs enter the market, the number of people taking it is expected to increase significantly.

Overall, the number of patients currently taking erdafitinib in China is not large. However, with the promotion of genetic screening and improved market accessibility, its application potential in patients with FGFR3-positive urothelial cancer is still huge.

References：https://www.balversa.com/